Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting

About this update from Assertio Holdings, Inc.

Late-breaking oral presentation highlights early signals of potential visual improvement and patient-reported outcomes of investigational ASP7317 in patients with advanced geographic atrophy (GA) Podium presentation focuses on the impact of IZERVAY ® (avacincaptad pegol intravitreal solution) on GA biomarker ellipsoid zone integrity Additional IZERVAY data highlight encore findings on driving eligibility, provide further GA biomarker insights and examine real-world treatment patterns in patients receiving anti-VEGF therapy NORTHBROOK, Ill., July 9, 2026 /PRNewswire/ -- Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") today announced new research insights at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, July 15-18, Montreal, Canada, that further advance understanding for geographic atrophy (GA) that will be presented. A late-breaking oral presentation will highlight preliminary Phase 1b results for ASP7317, an investigational retinal cell therapy for advanced GA and one of the first pluripotent stem cell-derived ophthalmic cell therapies to be tested in clinical trials. The presentation will include information on early signals of potential visual improvement, anatomical stabilization and patient-reported outcomes. Astellas' IZERVAY (avacincaptad pegol intravitreal solution), indicated for the treatment of GA secondary to age related macular degeneration (AMD), will also have a podium presentation revealing emerging data on the relationship between ellipsoid zone integrity (an earlier biomarker for GA measuring photoreceptor health) and low-luminance deficit. Additional IZERVAY data will further explore biomarkers associated with disease progression, functional outcomes and real-world treatment patterns in patients with GA secondary to AMD, including: Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma "Geographic atrophy has a substantial impact on patients' daily lives and wellbeing. The data presented at ASRS reflect our steadfast commitment to advancing understanding of the disease and exploring approaches that may address patient needs at different stages of GA. Through IZERVAY, we continue to generate evidence that deepens our understanding of disease progression and patient-relevant outcomes. At the same time, we are pioneering next-generation modalities such as ASP7317, our investigational retinal cell therapy for advanced GA. More broadly, our ambition in ophthalmology is to transform the management of currently irreversible retinal diseases."

View stock analysis, news, and events for Assertio Holdings, Inc.